StockData

DarioHealth vs Sonoma Pharmaceuticals

DRIO and SNOA side by side, both in surgical, medical, and dental instruments and supplies. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How DRIO and SNOA compare

DarioHealth is the larger company, worth 2.9 times as much as Sonoma Pharmaceuticals ($12.3M against $4.2M).

Sonoma Pharmaceuticals grew revenue faster over the last twelve months (47.0% versus −22.6% for DarioHealth).

Sonoma Pharmaceuticals keeps more of each dollar of sales as profit, with a net margin of −10.3% compared with −170% at DarioHealth.

Sonoma Pharmaceuticals scores higher on the StockData Score (11 against 8 for DarioHealth), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricDRIOSNOA
Size and price
Market cap$12.3M$4.2M
Share price$1.26$0.880
Change, 1 year−89.3%−75.1%
Change, 5 years−99.6%−99.2%
Beta (5Y)–2.09
Employees160250
StockData Score
Total score811 (better)
Valuation score4 (better)3
Growth score23 (better)
Performance score12 (better)
Health score13 (better)
Dividend score00
Valuation
P/E0.3×–
P/S0.6×0.2× (better)
P/B0.2× (better)0.6×
PEG0.01–
FCF yield−206%−63.0% (better)
Fair value$93.13$4.67
Margin of safety98.6% (better)81.2%
Growth
Revenue growth (TTM)−22.6%47.0% (better)
Revenue growth, 5Y average24.2% (better)0.95%
EPS growth, 5Y average20.3%–
Profitability
Gross margin58.2% (better)38.9%
Operating margin−152%−6.4% (better)
Net margin−170%−10.3% (better)
FCF margin−121%−12.1% (better)
Return on equity−59.9%−42.5% (better)
Return on invested capital−34.8% (better)−112%
Financial health
Debt / equity0.560.02 (better)
Interest coverage−7.0×–
Current ratio2.312.99 (better)
Altman Z-score−7.32 (better)−13.67
Piotroski F-score4 (better)3
Dividends and buybacks
Buyback yield–−94.0%
Shareholder yield0.00% (better)−94.0%
Ownership
Held by institutions15.0%2.3%
Held by insiders13.7%11.1%
Insider net buying, 12 months$100K–
Short interest, % of float1.4%1.6%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.